Beijing Beilu Pharmaceutical Co., Ltd. (SHE:300016)
9.63
+0.47 (5.13%)
Apr 29, 2026, 3:08 PM CST
SHE:300016 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 295.44 | 257.46 | 748.45 | 766.73 | 895.02 |
Trading Asset Securities | 379.75 | 350.77 | - | - | - |
Cash & Short-Term Investments | 675.18 | 608.23 | 748.45 | 766.73 | 895.02 |
Cash Growth | 11.01% | -18.73% | -2.38% | -14.33% | -11.71% |
Accounts Receivable | 265.14 | 176.36 | 188.55 | 112.67 | 142.52 |
Other Receivables | 3.11 | 9.54 | 5.87 | 8.39 | 5.81 |
Receivables | 268.25 | 185.9 | 194.42 | 121.06 | 148.33 |
Inventory | 383.75 | 362.09 | 244.86 | 276.22 | 250.01 |
Other Current Assets | 49.63 | 14.95 | 9.07 | 14 | 12.72 |
Total Current Assets | 1,377 | 1,171 | 1,197 | 1,178 | 1,306 |
Property, Plant & Equipment | 1,125 | 976.03 | 876.23 | 840.46 | 795.3 |
Long-Term Investments | 576.63 | 536.76 | 556.06 | 561.19 | 553.2 |
Goodwill | 46.92 | 46.92 | - | 31.82 | 51.23 |
Other Intangible Assets | 147.22 | 160.82 | 128.39 | 125.1 | 138.99 |
Long-Term Accounts Receivable | - | 1.43 | - | - | - |
Long-Term Deferred Tax Assets | 37 | 41.33 | 41.38 | 39.32 | 18.15 |
Long-Term Deferred Charges | 25.27 | 24.94 | 17.2 | 36.95 | 32.4 |
Other Long-Term Assets | 12.74 | 18.11 | 3.38 | 5.83 | 8.92 |
Total Assets | 3,348 | 2,978 | 2,819 | 2,819 | 2,904 |
Accounts Payable | 214.38 | 171.32 | 115.12 | 140.9 | 141.13 |
Accrued Expenses | 26.91 | 44.5 | 34.89 | 32.05 | 26.06 |
Short-Term Debt | 216.96 | 140.02 | 175.56 | 107.61 | 79.08 |
Current Portion of Long-Term Debt | 48.44 | 49 | 12.4 | 10.09 | 20.13 |
Current Portion of Leases | - | 3.26 | 3.04 | 2.74 | 0.27 |
Current Income Taxes Payable | 17.77 | - | - | - | 0.01 |
Current Unearned Revenue | 6.66 | 8.76 | 2.01 | 4.45 | 3.8 |
Other Current Liabilities | 43.28 | 38.38 | 16.14 | 4.83 | 15.09 |
Total Current Liabilities | 574.39 | 455.23 | 359.17 | 302.67 | 285.56 |
Long-Term Debt | 248.79 | 600.24 | 592.55 | 516.28 | 476.1 |
Long-Term Leases | 2.16 | 4.8 | 7.17 | 9.98 | 0.14 |
Long-Term Unearned Revenue | 24.52 | 16.84 | 11.74 | 7.89 | 10.45 |
Long-Term Deferred Tax Liabilities | 80.5 | 70.93 | 62.48 | 58.56 | 45.98 |
Total Liabilities | 930.36 | 1,148 | 1,033 | 895.39 | 818.22 |
Common Stock | 562.87 | 491.95 | 491.93 | 491.96 | 492.72 |
Additional Paid-In Capital | 697.91 | 135.34 | 135.22 | 135.3 | 201.27 |
Retained Earnings | 994.58 | 926.45 | 912.79 | 1,019 | 1,042 |
Treasury Stock | - | - | - | -0.1 | -9.06 |
Comprehensive Income & Other | 3.36 | 113.86 | 110.67 | 130.27 | 130.04 |
Total Common Equity | 2,259 | 1,668 | 1,651 | 1,776 | 1,857 |
Minority Interest | 158.45 | 161.9 | 135.69 | 146.88 | 229.03 |
Shareholders' Equity | 2,417 | 1,829 | 1,786 | 1,923 | 2,086 |
Total Liabilities & Equity | 3,348 | 2,978 | 2,819 | 2,819 | 2,904 |
Total Debt | 516.35 | 797.32 | 790.72 | 646.71 | 575.72 |
Net Cash (Debt) | 158.84 | -189.09 | -42.28 | 120.03 | 319.31 |
Net Cash Growth | - | - | - | -62.41% | 2.79% |
Net Cash Per Share | 0.31 | -0.42 | -0.09 | 0.21 | 0.66 |
Filing Date Shares Outstanding | 537.43 | 491.95 | 491.93 | 491.96 | 492.72 |
Total Common Shares Outstanding | 537.43 | 491.95 | 491.93 | 491.96 | 492.72 |
Working Capital | 802.42 | 715.95 | 837.62 | 875.34 | 1,021 |
Book Value Per Share | 4.20 | 3.39 | 3.36 | 3.61 | 3.77 |
Tangible Book Value | 2,065 | 1,460 | 1,522 | 1,619 | 1,667 |
Tangible Book Value Per Share | 3.84 | 2.97 | 3.09 | 3.29 | 3.38 |
Buildings | - | 700.49 | 561.7 | 557.21 | 532.04 |
Machinery | - | 567.37 | 503.01 | 470.31 | 400.02 |
Construction In Progress | - | 70.26 | 110.39 | 44.99 | 49 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.